Lercanidipine: Short plasma half-life, long duration of action. A molecular model to rationalize its pharmacokinetic properties

Journal of Cardiovascular Pharmacology

Volumn 29, Issue SUPPL. 1, 1997, Pages

  Herbette, Leo G ^a,b   Vecchiarelli, Michelle ^b   Leonardi, Amedeo ^c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c Recordati SpA   (Italy)

Author keywords

Ion channel receptor drug half life; Lercanidipine; Lipid bilayer; Lipophilicity; Membrane structure

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL; ISRADIPINE; LACIDIPINE; LERCANIDIPINE; NIMODIPINE; NITRENDIPINE;

ARTICLE; BINDING AFFINITY; BLOOD PRESSURE REGULATION; CELL MEMBRANE; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HYDROPHOBICITY; LIPID BILAYER; LIPOPHILICITY; PRIORITY JOURNAL;

EID: 0030952798     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199729001-00004     Document Type: Article

References (27)

1. Herbette LG, Rhodes DG, Mason RP, New approaches to drug design and delivery based on drug-membrane interactions. Drug Design Deliv 1991;7:75-118.
2. Herbette LG, Gaviraghi G, Tulenko T, Mason RP. Molecular interaction between lacidipine and biological membranes. J Hypertens 1993;11(suppl 1):S13-S9.
3. Herbette LG. Calcium antagonists: membrane binding, duration of action, and anti-atherosclerotic potential effect. JAMA 1994;SEA(suppl):10:2-8.
4. Tulenko TN. Athergenic activity of excess membrane cholesterol in arterial smooth muscle and endothelial cells. J Am Coll Cardiol 1991;17:24A.
5. Mason RP, Moisey DM, Shajenko L. Cholesterol alters the binding of Ca2+ channel blockers to the membrane lipid bilayer. Mol Pharm 1992;41:315-21.
6. Herbette LG, Mason PE, Sweeney KR, Trumbore MW, Mason RP. Favorable amphiphilicity of nimodipine facilitates its interactions with brain membranes. Neuropharmacology 1994;33:241-9.
7. Herbette LG, Mason RP, Tulenko T. Calcium antagonists and membrane binding - the unique properties of lacidipine. In: Van Zwieten PA, ed. Research and clinical forums. Vol. 16. Tunbridge, U.K.: Wells Medical, 1994;16:17-28.
8. Changeux J, Devillers-Thiery A, Chemouilli P. Acetylcholine receptor, an allosteric protein. Science 1984;225:1335-45.
9. Blanton M, McCardy E, Gallaher R, Wang HH. Noncompetitive inhibitors reach their binding site in the acetylcholine receptor by two different paths. Mol Pharm 1988;33:634-42.
10. Hille KB. Local anesthetics, hydrophilic and hydrophobia pathways for the drug receptor reaction. J Gen Physiol 1977;69:497-515.
11. Kobilk BK, Kobilka TS, Daniel K, Regan JW, Caron MG, Lefkowitz RJ. Chimeric alpha2-, beta2-Adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Science 1988;240:1310-16.
12. Herbette LG, Katz AM, Sturtevant JM. Comparisons of the interactions of propanalol and timolol with model and biological membrane systems. Mol Pharm 1983;24:259-69.
13. Takahashi M, Seagar MJ, Jones JF, Reber BFX, Catterall WA. Subunit structure of dihydropyridine-sensitive Ca+2 channels from skeletal muscle. Proc Natl Acad Sci USA 1987;84:5478-82.
14. Tanabe TH, Takeshima A, Mikami V, et al. Primary structure of the receptor for Ca+2 channel blockers from skeletal muscle. Nature 1987;328:313-8.
15. Yatani AD, Kuntze DL, Brown AM. Effects of dihydropyridine Ca+2 channel modulators on cardiac sodium channels. Am J Physiol 1988;254:H140-7.
16. Tanabe T. Voltage-dependent calcium channel - from structure to function. Tanpakushitsu Kakusan Koso 1991;36: 861-8.
17. Kokubun S, Reuter H, Dihydropyridine derivatives prolong the open state of Ca++ channel in cultured cardiac cells. Proc Natl Acad Sci USA 1984;81:4824-7.
18. Affolter H, Coronada R. The sidedness of reconstituted calcium channels from muscle transverse tubules. Biophys J 1986;48:341-7.
19. Janis RA, Silver PJ, Triggle DJ. Drug action and calcium regulation. Adv Drug Res 1987;16:309-589.
20. Janis RA, Triggle DJ. Pharmacology of calcium channels. In: Hurwitz L, Partridge LD and Leach JK, eds. Calcium channels - their properties, functions, regulation and clinical relevance. Boca Raton, FL: CRC Press, 1991:195-249.
21. Abernethy DR, Gutkowaka J, Winterbottom LM. Effects of amlodipine, a long acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. Clin Pharmacol Ther 1990;48:76-86.
22. Mason RP, Campbell S, Wang S, Herbette LG. A comparison of bilayer location and binding for the charged 1,4-dihydropyridine Ca+2 channel antagonist amlodipine with uncharged drugs of this class in cardiac and model membranes. J Mol Pharm 1989;36:634-40.
23. Herbette LG. Membrane pathways for drug/ion channel interactions: molecular basis for pharmacokinetic properties. Drug Dev Res 1994;33:214-24.
24. Abernethy DR. The pharmacokinetic profile of amlodipine. Am Heart J 1989;118:1100-3.
25. Micheli D, Collodel A, Semeraro C, Gaviraghi G, Carpi C. Lacidipine: a calcium antagonist with potent and long-lasting antihypertensive effects in animal studies. J Cardiol Pharm 1990;15:666-75.
26. Lombardo D, Raimondi F. Efficacy and safety: evaluation of lacidipine compared to amlodipine in mild to moderate hypertensive patients. J Cardiol Pharm 1994;Suppl 5:S98-100.
27. Rhodes DG, Sarmiento JG, Herbette LG. Kinetics of binding of membrane-active drugs to receptor sites. Diffusion limited rates for a membrane bilayer approach of 1,4-dihydropyridine Ca+2 channel antagonists to their active site. Mol Pharmacol 1985;27:612-23.